Skip to main content
An official website of the United States government

onvansertib

An orally bioavailable, adenosine triphosphate (ATP) competitive inhibitor of polo-like kinase 1 (PLK1; PLK-1; STPK13), with potential antineoplastic activity. Upon administration, onvansertib selectively binds to and inhibits PLK1, which disrupts mitosis and induces selective G2/M cell-cycle arrest followed by apoptosis in PLK1-overexpressing tumor cells. PLK1, named after the polo gene of Drosophila melanogaster, is a serine/threonine kinase that is crucial for the regulation of mitosis, and plays a key role in tumor cell proliferation. PLK1 expression is upregulated in a variety of tumor cell types and high expression is associated with increased aggressiveness and poor prognosis.
Synonym:PLK-1 inhibitor PCM-075
PLK1 inhibitor PCM-075
polo-like kinase 1 inhibitor NMS-1286937
polo-like kinase 1 inhibitor PCM-075
Code name:NMS-1286937
PCM 075
PCM-075
Search NCI's Drug Dictionary